A study of human cancer cells (THLE-2 and HuH7) found APO10LA treatment to exert its chemopreventive effects by increasing hepatic SIRT1 protein; deacetyling SIRT1 targets, decreasing caspase-1 activation and SIRT1 protein cleavage; lowering the expression of proinflammatory interleukins such as TNFα, IL-6, NF-κB, and p65; and increasing STAT3 activation [138]. Here, IL6 is linked to cancer.